Biora Therapeutics (BIOR) Competitors $0.12 -0.01 (-6.98%) As of 04/17/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock BIOR vs. THAR, PTPI, PTIX, QLGN, ELAB, GLMD, ZVSA, PBM, CERO, and ENTOShould you be buying Biora Therapeutics stock or one of its competitors? The main competitors of Biora Therapeutics include Tharimmune (THAR), Petros Pharmaceuticals (PTPI), Protagenic Therapeutics (PTIX), Qualigen Therapeutics (QLGN), Elevai Labs (ELAB), Galmed Pharmaceuticals (GLMD), ZyVersa Therapeutics (ZVSA), Psyence Biomedical (PBM), CERo Therapeutics (CERO), and Entero Therapeutics (ENTO). These companies are all part of the "pharmaceutical products" industry. Biora Therapeutics vs. Tharimmune Petros Pharmaceuticals Protagenic Therapeutics Qualigen Therapeutics Elevai Labs Galmed Pharmaceuticals ZyVersa Therapeutics Psyence Biomedical CERo Therapeutics Entero Therapeutics Tharimmune (NASDAQ:THAR) and Biora Therapeutics (NASDAQ:BIOR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, community ranking, earnings, media sentiment and risk. Which has higher earnings and valuation, THAR or BIOR? Tharimmune has higher earnings, but lower revenue than Biora Therapeutics. Tharimmune is trading at a lower price-to-earnings ratio than Biora Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTharimmuneN/AN/A-$9.32M-$9.74-0.11Biora Therapeutics$892K0.59-$124.11M-$13.04-0.01 Do analysts rate THAR or BIOR? Tharimmune presently has a consensus target price of $17.00, indicating a potential upside of 1,451.09%. Biora Therapeutics has a consensus target price of $23.00, indicating a potential upside of 19,524.57%. Given Biora Therapeutics' higher probable upside, analysts clearly believe Biora Therapeutics is more favorable than Tharimmune.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Biora Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor THAR or BIOR? In the previous week, Tharimmune had 2 more articles in the media than Biora Therapeutics. MarketBeat recorded 2 mentions for Tharimmune and 0 mentions for Biora Therapeutics. Biora Therapeutics' average media sentiment score of 0.00 beat Tharimmune's score of -0.03 indicating that Biora Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Tharimmune Neutral Biora Therapeutics Neutral Which has more risk and volatility, THAR or BIOR? Tharimmune has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Biora Therapeutics has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500. Do institutionals & insiders hold more shares of THAR or BIOR? 1.2% of Tharimmune shares are owned by institutional investors. Comparatively, 43.7% of Biora Therapeutics shares are owned by institutional investors. 2.4% of Tharimmune shares are owned by company insiders. Comparatively, 51.1% of Biora Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community believe in THAR or BIOR? Biora Therapeutics received 6 more outperform votes than Tharimmune when rated by MarketBeat users. However, 100.00% of users gave Tharimmune an outperform vote while only 80.00% of users gave Biora Therapeutics an outperform vote. CompanyUnderperformOutperformTharimmuneOutperform Votes2100.00% Underperform VotesNo VotesBiora TherapeuticsOutperform Votes880.00% Underperform Votes220.00% Is THAR or BIOR more profitable? Biora Therapeutics' return on equity of 0.00% beat Tharimmune's return on equity.Company Net Margins Return on Equity Return on Assets TharimmuneN/A -167.63% -130.18% Biora Therapeutics N/A N/A -332.47% SummaryTharimmune and Biora Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Biora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BIOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIOR vs. The Competition Export to ExcelMetricBiora TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$530,000.00$6.46B$5.31B$7.35BDividend YieldN/A3.20%5.45%4.29%P/E Ratio-0.016.9521.9417.82Price / Sales0.59231.03380.9597.68Price / CashN/A65.6738.2634.64Price / Book0.005.936.453.98Net Income-$124.11M$143.22M$3.22B$247.81M1 Month Performance-26.75%-13.56%-9.76%-7.91%1 Year Performance-98.09%-8.89%11.49%1.53% Biora Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIORBiora TherapeuticsN/A$0.12-7.0%$23.00+19,524.6%-98.0%$530,000.00$892,000.00-0.01120Gap UpTHARTharimmune2.1737 of 5 stars$1.17+2.1%$17.00+1,347.4%-80.7%$2.48MN/A-0.122Short Interest ↑PTPIPetros Pharmaceuticals0.2739 of 5 stars$0.05-3.4%N/A-94.1%$2.46M$5.11M-0.0120Short Interest ↑Gap DownPTIXProtagenic Therapeutics1.5486 of 5 stars$0.31+3.0%N/A-82.5%$2.33MN/A-0.242Short Interest ↓Positive NewsGap DownQLGNQualigen TherapeuticsN/A$3.10+3.3%N/A-79.4%$2.28M$4.98M0.0050Short Interest ↑Gap DownELABElevai Labs0.4524 of 5 stars$3.18+3.6%N/A-99.7%$2.25M$2.45M-0.0518Short Interest ↑GLMDGalmed Pharmaceuticals1.0638 of 5 stars$1.33+0.8%N/A-69.5%$2.20MN/A-0.0820Short Interest ↑News CoverageZVSAZyVersa Therapeutics1.1922 of 5 stars$0.85+10.4%N/A-88.8%$2.18MN/A0.002Short Interest ↓High Trading VolumePBMPsyence BiomedicalN/A$0.47+5.1%N/A-99.1%$2.14MN/A0.00N/ANews CoverageGap UpCEROCERo TherapeuticsN/A$0.67-4.1%N/A-99.6%$2.03MN/A0.008Short Interest ↓ENTOEntero Therapeutics0.5745 of 5 stars$0.41+4.4%N/AN/A$1.94MN/A0.009Positive NewsGap Down Related Companies and Tools Related Companies Tharimmune Competitors Petros Pharmaceuticals Competitors Protagenic Therapeutics Competitors Qualigen Therapeutics Competitors Elevai Labs Competitors Galmed Pharmaceuticals Competitors ZyVersa Therapeutics Competitors Psyence Biomedical Competitors CERo Therapeutics Competitors Entero Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIOR) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BIOR Stock Free BIOR Stock Alerts